This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
The mission of Lineage Cell Therapeutics is to deliver on some of the early promises of cell therapy. Cell therapy as a concept is a wonderful idea, but many of the early efforts never generated the kind of clinical data that gets people excited and leads to new medicines. In some cases, cell therapy can be curative for the patient.
By directly interfering with the eIF4F complex, eFFECTOR’s STRIs provide a promising avenue for disrupting the core mechanisms of cancer, offering the potential to improve patient outcomes and overcome the limitations of traditional cancer therapies. Prior to Anadys Pharmaceuticals, Inc., and Vice President at WarnerLambert Co.,
Since the last Codon Digest, I’ve published: Reasons to Be Grateful for Biotechnology (with Avadhoot Jadhav) AAV Foundations (Part I) An overview of AAV-based gene therapies, how they get made, and where they go wrong. I pulled them from a 2011 blog post ( oH mY goD tHat’S nOt pEEr-ReVieWeD!!! ) Let’s be real.
Since the last Codon Digest, I’ve published: Reasons to Be Grateful for Biotechnology (with Avadhoot Jadhav) AAV Foundations (Part I) An overview of AAV-based gene therapies, how they get made, and where they go wrong. I pulled them from a 2011 blog post ( oH mY goD tHat’S nOt pEEr-ReVieWeD!!! ) Let’s be real.
Nature (2011). Journal of MolecularBiology (1961). Link (Golden Gate assembly) Other Basic Methods & Cloning →Basic Methods in Cellular and MolecularBiology , by multiple authors. Link Molecular Cloning Techniques , by AddGene. Link Molecular Cloning Techniques , by AddGene. & Xie X.S.
Nature (2011). Journal of MolecularBiology (1961). Link (Golden Gate assembly) Other Basic Methods & Cloning →Basic Methods in Cellular and MolecularBiology , by multiple authors. Link Molecular Cloning Techniques , by AddGene. Link Molecular Cloning Techniques , by AddGene. & Xie X.S.
We organize all of the trending information in your field so you don't have to. Join 15,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content